Effects of Empagliflozin on Fluid Overload, Weight and Blood Pressure in Chronic Kidney Disease.
Kaitlin J MayneNatalie StaplinDavid F KeaneChristoph WannerSusanne BrennerVladimir CejkaJohannes StegbauerParminder K JudgeDavid PreissJonathan R EmbersonDaniele TrincaRejive DayanandanRyonfa LeeJohn NolanAkiko OmataJennifer B GreenDavid Zi CherneyLai-Seong HooiRoberto PontremoliKatherine R TuttleJennifer Susan LeesPatrick B MarkSimon J DaviesSibylle J HauskeDominik SteublMartina BrueckmannMartin J LandrayColin Baigent FMedSciRichard HaynesWilliam G Herringtonnull nullPublished in: Journal of the American Society of Nephrology : JASN (2023)
In a broad range of patients with CKD, empagliflozin resulted in a sustained reduction in a bioimpedance-derived estimate of fluid overload, with no statistically significant effect on fat mass.